Best Practices for Bringing Liquid Biopsy In-house

Funding comes after the company meets key milestones with new collaborations and studies, product enhancements, and reimbursement progress.

DeciBio interviewed Canexia Health's Brady Davis to discuss how Canexia Health and Project ACTT (Access to Testing and Treatment) are leveraging Canexia’s tech transfer platform and liquid biopsy test, Follow IT, to bridge the gap between the Canadian cancer community and molecular testing during the COVID-19 pandemic.

British Columbia-based Digital Technology Supercluster has announced a cumulative investment of approximately $30 million into 17 projects, including Project ACTT led by Canexia Health, through its COVID-19 program, launched in April to contribute to Canada’s Plan to Mobilize Industry to fight the pandemic.